Drug Co-Packaging Proposed Rule Could Hamper Some OTC Marketing
This article was originally published in The Pink Sheet
Executive Summary
OTC drug packages with separate containers of a product's daytime and nighttime formulations could be mislabeled under US FDA’s proposed rule, as well as co-packaged products with little similarity in use, such as an oral analgesic sold in tandem with a topical pain relief product.
You may also be interested in...
‘From Excedrin’ Greets Consumers At Top Of Haleon’s Head Care Supplement Packages
UK firm adds Excedrin brand to packages for Head Care Proactive Health, Replenish +Focus and Replenish +Sleep supplements. Voltaren brand added to packaging for supplement formulations intended to improve mobility and reduce joint paint.
Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”